Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
EMBO Reports|November 18, 2016
Resetting cancer stem cell regulatory nodes upon MYC inhibitionSilvia Galardi, Mauro Savino, Fiorella Scagnoli, et al.
Neurology|September 30, 2022
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective StudyAnna Luisa Di Stefano, Lucia Nichelli, Giulia Berzero, et al.
Nature Communications|October 5, 2016
A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathwaysTianzhi Huang, Angel A Alvarez, Rajendra P Pangeni, et al.
Neuro-Oncology Advances|July 10, 2020
Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapyMarica Eoli, Cristina Corbetta, Elena Anghileri, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
The Lancet. Oncology|November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupHideho Okada, Michael Weller, Raymond Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 26, 2006
Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatmentMaura Massimino, Felice Giangaspero, Maria Luisa Garrè, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Nature Genetics|June 9, 2016
Clonal evolution of glioblastoma under therapyJiguang Wang, Emanuela Cazzato, Erik Ladewig, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Pageof 18